IPSEN (IPN.PA) Stock Overview
Europe - EPA:IPN - FR0010259150 - Common Stock
IPN.PA Key Statistics, Chart & Performance
The current stock price of IPN.PA is 121.8 EUR. In the past month the price increased by 9.14%. In the past year, price increased by 5.64%.
IPN.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1LLY.MI | ELI LILLY & CO | 51.52 | 678.33B | ||
| LLY.DE | ELI LILLY & CO | 51.52 | 678.23B | ||
| ZEG.DE | ASTRAZENECA PLC | 18.87 | 444.61B | ||
| 1JNJ.MI | JOHNSON & JOHNSON | 18.48 | 397.91B | ||
| JNJ.DE | JOHNSON & JOHNSON | 18.32 | 394.53B | ||
| RHO.DE | ROCHE HOLDING AG-BR | 14.45 | 248.76B | ||
| 1ROG.MI | ROCHE HOLDING AG-GENUSSCHEIN | 13.92 | 239.54B | ||
| 1NOVN.MI | NOVARTIS AG-REG | 15.01 | 218.75B | ||
| NOT.DE | NOVARTIS AG-REG | 14.96 | 218.05B | ||
| 1SAN.MI | SANOFI | 14.49 | 217.12B | ||
| SNW.DE | SANOFI | 14.45 | 216.58B | ||
| SAN.PA | SANOFI | 14.44 | 216.39B |
Related stock screener links
About IPN.PA
Company Profile
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience, and rare diseases. The company is headquartered in Boulogne-Billancourt, Ile-De-France and currently employs 5,358 full-time employees. The company went IPO on 2005-12-06. The firm operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.
Company Info
IPSEN
65 Quai Georges Gorse
Boulogne-Billancourt ILE-DE-FRANCE FR
Employees: 5358
Phone: 33158335000
IPSEN / IPN.PA FAQ
What does IPN do?
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience, and rare diseases. The company is headquartered in Boulogne-Billancourt, Ile-De-France and currently employs 5,358 full-time employees. The company went IPO on 2005-12-06. The firm operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.
Can you provide the latest stock price for IPSEN?
The current stock price of IPN.PA is 121.8 EUR. The price increased by 0.5% in the last trading session.
What is the dividend status of IPSEN?
IPSEN (IPN.PA) has a dividend yield of 1.16%. The yearly dividend amount is currently 1.2.
What is the ChartMill technical and fundamental rating of IPN stock?
IPN.PA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Is IPSEN (IPN.PA) expected to grow?
The Revenue of IPSEN (IPN.PA) is expected to grow by 7.07% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of IPN stock?
IPSEN (IPN.PA) has a market capitalization of 10.21B EUR. This makes IPN.PA a Large Cap stock.
What is the next earnings date for IPN stock?
IPSEN (IPN.PA) will report earnings on 2026-02-11, after the market close.
IPN.PA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to IPN.PA. When comparing the yearly performance of all stocks, IPN.PA turns out to be only a medium performer in the overall market: it outperformed 52.95% of all stocks.
IPN.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to IPN.PA. IPN.PA has an excellent financial health rating, but there are some minor concerns on its profitability.
IPN.PA Financial Highlights
Over the last trailing twelve months IPN.PA reported a non-GAAP Earnings per Share(EPS) of 10.27. The EPS increased by 12.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 11.91% | ||
| ROA | 6.56% | ||
| ROE | 10.59% | ||
| Debt/Equity | 0.2 |
IPN.PA Forecast & Estimates
18 analysts have analysed IPN.PA and the average price target is 130.09 EUR. This implies a price increase of 6.81% is expected in the next year compared to the current price of 121.8.
For the next year, analysts expect an EPS growth of 5.2% and a revenue growth 7.07% for IPN.PA